Among the ICI combination regimens included in this study, pembrolizumab in combination with ipilimumab had the highest ROR (14.9, 95%CI 3.7-59.9), while the ROR (10, 95% CI 7.6-13.1) for nivolumab in combination with ipilimumab was higher than that for the vast majority of ICI monotherapy, which may indicate that patients treated with anti-PD-1 in combination with anti-CTLA-4 are more likely to be at increased risk of ICIs-induced ITP. The gene discussed is PDCD1; the disease is autoimmune thrombocytopenic purpura.